INHIBIKASE THERAPEUTICS INC - COM (IKT)

CUSIP: 45719W106

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / COM
Total 13F shares
3,794,682
Share change
+2,436,126
Total reported value
$10,625,000
Price per share
$2.80
Number of holders
13
Value change
+$6,720,225
Number of buys
11
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP 45719W106?
CUSIP 45719W106 identifies IKT - INHIBIKASE THERAPEUTICS INC - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INHIBIKASE THERAPEUTICS INC - COM (IKT) as of Q2 2021

As of 30 Jun 2021, INHIBIKASE THERAPEUTICS INC - COM (IKT) was held by 13 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,794,682 shares. The largest 10 holders included ACT Capital Management, LLC, Kepos Capital LP, VANGUARD GROUP INC, FMR LLC, SABBY MANAGEMENT, LLC, Murchinson Ltd., Antara Capital LP, Altium Capital Management LP, ZEKE CAPITAL ADVISORS, LLC, and Warberg Asset Management LLC. This page lists 13 institutional shareholders reporting positions in this security for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.